Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis
This study has been completed.
Study NCT00035334 Information provided by Bellus Health Inc
First Received: May 2, 2002 Last Updated: February 13, 2006
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Secondary (AA) Amyloidosis
Rheumatoid Arthritis
Nephrotic Syndrome
Familial Mediterranean Syndrome
Kidney Diseases
Gastrointestinal Diseases
Additional conditions recognized in this trial
Amyloidosis
Arthritis
Arthritis, Rheumatoid
Neoplasm Metastasis
Syndrome
More general conditions related to this trial
Autoimmune Diseases
Connective Tissue Diseases
Digestive System Diseases
Disease
Immune System Diseases
Joint Diseases
Metabolic Diseases
Musculoskeletal Diseases
Neoplasms
Neoplastic Processes
Nephrosis
Pathologic Processes
Rheumatic Diseases
Urologic Diseases
Sponsors listed in this trial
Bellus Health Inc
FDA Office of Orphan Products Development
Back to top of Main Content
